Filing Analysis
Jaguar Health, Inc. announced the completion of a conversion of its Series O Preferred Stock into Common Stock on June 25, 2026. This follows a previously executed special dividend and a 1-for-35 reverse stock split that occurred in April 2026.
🚩 Red Flags
- Recent history of a 1-for-35 reverse stock split (April 30, 2026), which is often a sign of extreme share price depression or delisting risk.
- Significant dilution: The conversion and warrant exercises will result in the issuance of nearly 840,000 new shares into a relatively small float.
📋 Key Facts
- Conversion of Series O Preferred Stock completed on June 25, 2026.
- Conversion ratio: 3.209 shares of Common Stock for each share of Series O Preferred Stock.
- Post-conversion outstanding Common Stock: 4,857,211 shares.
- Warrant holders are entitled to up to 839,000 shares upon exercise (comprising Warrant Shares and Conversion Shares).
- The filing retroactively adjusts dividend figures to account for a 1-for-35 reverse stock split effective April 30, 2026.
Jaguar Health, Inc. entered into two separate exchange agreements with Iliad Research and Trading, L.P. to retire Series M Preferred Stock in exchange for common stock and pre-funded warrants. These transactions result in significant potential dilution of existing shareholders.
🚩 Red Flags
- Significant potential dilution: The issuance of over 2 million shares via common stock and warrants represents substantial dilution for current shareholders.
- Debt/Preferred Stock conversion pattern: The company is using equity (common stock) to retire preferred stock, which often indicates a need to clean up the capital structure or manage liquidity at the expense of equity holders.
📋 Key Facts
- First Exchange Agreement (Dec 9, 2025): Issued 400,000 shares of Common Stock and a pre-funded warrant to purchase 1,304,545 shares in exchange for 75 shares of Series M Preferred Stock.
- Second Exchange Agreement (Dec 11, 2025): Issued 40,000 shares of Common Stock and a pre-funded warrant to purchase 304,827 shares in exchange for 16 shares of Series M Preferred Stock.
- Total new common stock issuance: 440,000 shares via direct issuance plus warrants for 1,609,372 shares.
- Pre-funded warrants are exercisable at $0.001 per share and include a 9.99% ownership cap to prevent beneficial ownership exceeding that threshold upon exercise.
Jaguar Health, Inc. held a special meeting of stockholders where shareholders approved two critical proposals required for Nasdaq compliance regarding the issuance of new securities. The approval includes shares issuable upon redemption of Series N Preferred Stock and shares/warrants related to a recent PIPE (Private Investment in Public Equity) transaction.
🚩 Red Flags
- Reliance on Nasdaq Rule 5635(d) approvals indicates the company was facing potential delisting risks due to exceeding shareholder approval thresholds for share issuances.
- Heavy use of Preferred Stock (Series L, M, and N) with significant voting caps suggests a complex capital structure common in distressed or highly leveraged micro-caps.
📋 Key Facts
- Special Meeting held on December 8, 2025.
- Proposal 1: Approval of issuance of Common Stock issuable upon exchange/redemption of Series N Preferred Stock per Nasdaq Rule 5635(d). Approved with 1,032,716 votes 'For'.
- Proposal 2: Approval of issuance of New PIPE Shares and a Pre-Funded PIPE Warrant per Nasdaq Rule 5635(d). Approved with 2,049,724 votes 'For'.
- Proposal 3: Approval to adjourn the meeting if necessary. Approved with 2,058,277 votes 'For'.
- The voting results were based on shares outstanding as of the October 31, 2025 record date.
Jaguar Health, Inc. entered into multiple amendments to royalty interests and a secured promissory note with Streeterville Capital, LLC, alongside an equity exchange transaction. The company is restructuring significant debt obligations and issuing common stock to settle preferred shares.
🚩 Red Flags
- Significant dilution: Issuance of 361,271 common shares to settle preferred stock.
- Liquidity pressure: Guaranteed monthly royalty payments of $750,000 starting April 2026 represent a significant cash outflow obligation.
- Debt restructuring/extension: Extending the maturity of a $6.2M note suggests potential difficulty in meeting original repayment terms.
- Multiple items in one filing (1.01, 2.03, 3.02) indicating complex financial maneuvering.
📋 Key Facts
- Amended three royalty interests (totaling $36M original principal) with Iliad Research, Uptown Capital, and Streeterville Capital; effective April 1, 2026, monthly payments will be the greater of $750,000 or actual royalties.
- Extended maturity date of a $6,220,812.50 secured promissory note with Streeterville Capital to April 1, 2026.
- Entered into an exchange agreement issuing 361,271 shares of common stock to Streeterville Capital in exchange for the cancellation of 25 shares of Series M Preferred Stock.
- The royalty interest amendments involve original principal amounts from October 2020 ($12M), December 2020 ($12M), and August 2022 ($12M).
Jaguar Health, Inc. entered into a $10.81 million secured promissory note agreement with Streeterville Capital, LLC on November 12, 2025. The financing includes significant restrictive covenants and a Deposit Account Control Agreement (DACA) where $8 million of the proceeds is held in a restricted account.
🚩 Red Flags
- Highly restrictive covenants: Lender must approve any 'Restricted Issuances' or changes to capital structure/debt.
- Liquidity constraint: $8 million of the $10.81 million is locked in a Deposit Account with strict withdrawal rules.
- Default penalties: Interest jumps to 18% per annum upon an Event of Default.
- Trigger events allow Lender to increase the outstanding balance by up to 15% (Major) or 5% (Minor) per occurrence.
- Lender has significant control over JAGX Sub, including prohibiting it from issuing debt or conducting business without consent.
📋 Key Facts
- Issued a secured promissory note for $10,810,000 to Streeterville Capital, LLC on November 12, 2025.
- Note carries an 8.00% annual interest rate with a 36-month maturity term.
- $8,000,000 of the proceeds was deposited into a restricted account at Lakeside Bank under a DACA.
- The note includes an original issue discount (OID) of $800,000 and $10,000 in transaction costs.
- Lender has the right to redeem up to $600,000 plus interest monthly starting on the 12-month anniversary.
- Mandatory prepayment required upon certain IP Transactions (up to 25% of upfront licensing fees).
Jaguar Health, Inc. entered into a privately negotiated exchange agreement to settle a portion of an outstanding royalty interest. The company issued 286,532 shares of common stock in exchange for a $600,000 reduction in the holder's balance.
🚩 Red Flags
- Equity dilution for existing shareholders via issuance of common stock to settle a liability.
📋 Key Facts
- Date of transaction: September 30, 2025
- Shares issued: 286,532 shares of common stock
- Debt/Liability reduction: $600,000 reduction in outstanding royalty interest balance
- Transaction type: Privately negotiated exchange agreement under Section 3(a)(9) of the Securities Act
Jaguar Health, Inc. entered into a PIPE financing agreement with Brown Stone Capital Limited on September 28, 2025. The company will issue common stock and pre-funded warrants to raise capital for working capital and debt repayment.
🚩 Red Flags
- Dilutive financing via pre-funded warrants (high volume of warrants relative to shares)
- Use of proceeds includes repayment of existing convertible notes, indicating a need to manage debt obligations
- Potential for significant downward pressure on stock price upon registration/resale of securities
📋 Key Facts
- Date of Agreement: September 28, 2025
- Investor: Brown Stone Capital Limited
- Securities issued: 161,583 shares of common stock and 479,442 pre-funded warrants
- Price per share/warrant: $1.56 (minus $0.0001 for warrants)
- Use of proceeds: Working capital, general corporate purposes, and repayment of existing convertible notes
- Registration requirement: Company must file a Form S-3 by October 9, 2025, to register resale of securities
Jaguar Health, Inc. entered into a PIPE financing agreement to issue approximately 951 shares of Series N Perpetual Preferred Stock for $2.38 million. The proceeds are intended for working capital and the repayment of existing notes.
🚩 Red Flags
- Dilution risk: The issuance involves preferred stock that is exchangeable for common stock, which will lead to significant dilution upon conversion/exchange.
- Debt repayment use of funds: Using new equity proceeds to repay existing notes can be a sign of liquidity pressure.
- Mandatory Exchange Rights: The company holds the right to force the exchange of preferred shares into common stock, potentially creating sudden downward selling pressure on the market.
📋 Key Facts
- Transaction type: Private Placement (PIPE) closed on September 10, 2025.
- Aggregate purchase price: Approximately $2.38 million.
- Security issued: Series N Perpetual Preferred Stock with a stated value of $2,500 per share.
- Use of proceeds: Working capital and repayment of existing notes.
- Conversion/Exchange: Shares are exchangeable for Common Stock subject to stockholder approval; the Company has mandatory exchange rights once approved.
- Registration requirement: The company must file an S-3 registration statement within 30 days of closing to register resale of these shares.
Jaguar Health, Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025, where stockholders approved seven proposals including director elections and auditor ratification.
🚩 Red Flags
- Approval of multiple share issuances (Series L, Series M, and Convertible Notes) suggests ongoing dilution for existing shareholders.
- The company is utilizing Nasdaq Rule 5635(d) waivers to issue shares, which typically indicates a need to satisfy specific exchange requirements related to prior issuances or debt obligations.
📋 Key Facts
- Three Class I directors (James J. Bochnowski, Lisa A. Conte, Jonathan B. Siegel) were elected to three-year terms ending in 2028.
- RBSM LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved an amendment to the 2014 Stock Incentive Plan to increase authorized shares by 307,670 and extend its term by ten years.
- Shareholders approved Nasdaq Rule 5635(d) issuances for Series L and Series M Perpetual Preferred Stock exchangeable for common stock.
- Shareholders approved the issuance of up to 1,409,732 shares upon conversion of 6% convertible promissory notes and related warrants.
Jaguar Health, Inc. entered into a Sixth Amendment to its existing At-the-Market (ATM) offering agreement on August 14, 2025. The amendment extends the term of Lucid Capital Markets, LLC as a Manager through December 31, 2025.
🚩 Red Flags
- Continued use of ATM offerings often indicates a need for liquidity/cash runway management, though common in micro-caps.
📋 Key Facts
- Entered into Sixth ATM Amendment with Ladenburg Thalmann & Co. Inc. and Lucid Capital Markets, LLC on August 14, 2025.
- The amendment retrospectively extends Lucid's term as a Manager from June 30, 2025, to December 31, 2025.
- After December 31, 2025, Ladenburg Thalmann & Co. Inc. will serve as the sole Manager under the agreement.
- The company filed a supplement to its existing prospectus relating to this amendment.
Jaguar Health, Inc. entered into two private exchange agreements to reduce outstanding royalty interest debt by issuing Series M Perpetual Preferred Stock to Iliad Research and Trading, L.P. and Streeterville Capital, LLC.
🚩 Red Flags
- Significant debt restructuring via equity issuance suggests liquidity constraints or pressure to reduce royalty obligations.
- The Series M Preferred Stock includes a liquidation preference that must be paid before common stockholders.
- Accruing preferred return (up to 10%) will lead to further dilution of common shareholders over time.
📋 Key Facts
- The company issued 170 shares of Series M Preferred Stock to Iliad in exchange for a $4,250,000 reduction in the October 2020 Royalty Interest.
- The company issued 90 shares of Series M Preferred Stock to Streeterville in exchange for a $2,250,000 reduction in the August 2022 Royalty Interest.
- Total debt reduction via equity issuance: $6,500,000.
- Series M Preferred Stock features an as-converted voting right with a 9.99% ownership cap.
- Preferred stock carries a liquidation preference and an accruing preferred return (10% for years 1-2, 8% for years 3-4, and 6% thereafter) payable in additional shares.
Jaguar Health, Inc. entered into an agreement to exchange approximately $2.57 million of existing convertible promissory notes for new 6% convertible notes and issued warrants to certain investors. The transaction involves significant dilution potential through the issuance of up to 928,582 new warrant shares and conversion shares.
🚩 Red Flags
- Significant potential dilution via new warrants and convertible notes
- Insider participation in a debt-for-equity exchange transaction (Related Party)
- Restrictive covenants on capital distributions/dividends
- Requirement to file registration statement for resale within 30 days, indicating immediate liquidity for investors at the expense of shareholders
📋 Key Facts
- Exchange Transaction Date: June 24, 2025
- Replacement Notes Principal: ~$2.57 million at 6% interest maturing January 30, 2026
- Conversion Price: $5.535 (non-insiders) and $5.555 (insiders)
- New Warrants: Up to 928,582 shares of Common Stock at an exercise price of $2.70
- Insider Participation: CEO and certain board members participated in the exchange ($492,012 principal amount)
- Restrictive Covenant: Net proceeds from financing/licensing exceeding $8M must be used to repay Replacement Notes
Jaguar Health, Inc. entered into a securities purchase agreement to conduct a registered direct offering of 246,306 shares at $6.09 per share, alongside a concurrent private placement of warrants. The company intends to use the approximately $1.5 million in gross proceeds for working capital and debt repayment.
🚩 Red Flags
- Significant dilution potential due to the issuance of 492,612 warrants (double the number of shares in the primary offering) at a below-market exercise price ($5.84 vs $6.09).
- Warrant overhang: The inclusion of both investor warrants and placement agent warrants creates significant future dilution.
- Use of proceeds includes repayment of convertible promissory notes, which may indicate a need to manage existing debt obligations.
📋 Key Facts
- Registered direct offering of 246,306 common shares priced at $6.09 per share.
- Aggregate gross proceeds estimated at approximately $1,500,000 before fees.
- Concurrent private placement of 492,612 warrants with an exercise price of $5.84 per share.
- Warrants are immediately exercisable and expire in 24 months or upon fundamental/liquidation events.
- H.C. Wainwright & Co., LLC acting as placement agent with a 7% cash fee and 1% management fee.
- Issuance of 'Wainwright Warrants' representing 6% of the shares sold, with an exercise price of $7.6125 (125% of offering price).
- Proceeds earmarked for working capital, operating expenses, and repayment of convertible promissory notes.
Jaguar Health, Inc. entered into multiple debt-for-equity exchange agreements to reduce outstanding royalty obligations and restructure preferred stock. The company issued common and Series L preferred shares to Iliad Research and Trading, L.P. and Streeterville Capital, LLC in exchange for reductions in debt balances.
🚩 Red Flags
- Aggressive debt restructuring via equity issuance (dilutive to common shareholders).
- Series L Preferred Stock includes a 'Floor Price' ($1.32) which acts as a downside protection for preferred holders, potentially creating significant dilution if the stock trades below this level.
- High preferred return rates (up to 15%) on Series L shares increase future dilution risk.
📋 Key Facts
- Issued 60,000 shares of Common Stock to Iliad to reduce the October 2020 Royalty Interest by $466,200 (May 13, 2025).
- Exchanged all outstanding 99.3822 shares of Series J Preferred Stock for 99.3822 shares of new Series L Perpetual Preferred Stock with Streeterville Capital, LLC (May 14, 2025).
- Issued 22 shares of Series L Preferred Stock to Iliad to reduce the October 2020 Royalty Interest by $550,000 (May 14, 2025).
- Series L Preferred Stock features a 'Floor Price' for liquidation/conversion purposes set at $1.32 per share.
- Series L Preferred Stock carries a preferred return: 0% for years 1-2, 10% for years 3-4, and 15% thereafter.
Jaguar Health, Inc. filed an 8-K to furnish an investor presentation made available on its website. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The company released an investor presentation dated May 2025.
- The presentation was made available via the company's official website (https://jaguarhealth.gcs-web.com/events-and-presentations).
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Jaguar Health, Inc. announced that a majority of investors from its March 2025 $3.4 million convertible note offering have executed limited waivers regarding issuance restrictions. These waivers allow the company to issue certain additional securities despite previous 'Variable Rate Transaction' (VRT) restrictions.
🚩 Red Flags
- Previous existence of VRT (Variable Rate Transaction) restrictions often indicates highly protective terms for lenders/investors, common in distressed micro-cap financing.
- The need to waive these restrictions suggests the company requires more flexible capital access than its current debt structure allows.
📋 Key Facts
- On May 5, 2025, investors holding a majority of existing Securities executed a Limited Waiver.
- The original $3.4 million offering involved 6% convertible promissory notes and warrants issued on March 26, 2025.
- The waiver permits the company to issue certain additional securities that were previously restricted under 'Variable Rate Transaction' terms.
- The restriction originally applied for one year from the date the registration statement for resale is declared effective by the SEC.
Jaguar Health, Inc. entered into a privately negotiated exchange agreement to reduce an outstanding royalty interest balance by issuing common stock.
🚩 Red Flags
- Issuance of equity to settle debt/royalty obligations can indicate liquidity constraints or a preference for using stock over cash to manage liabilities.
- The transaction involves a 'holder of royalty interest,' which often implies non-standard, potentially related-party or structured financing arrangements common in micro-cap companies.
📋 Key Facts
- Date of event: April 30, 2025.
- The Company issued 57,500 shares of common stock to a holder of a royalty interest.
- The issuance was in exchange for a $632,500 reduction in the outstanding balance of the royalty interest.
- The transaction was conducted under Section 3(a)(9) of the Securities Act of 1933 (exemption from registration).
Jaguar Health, Inc. announced initial proof-of-concept results from an investigator-initiated trial regarding a novel liquid formulation of crofelemer. The data indicates improvements in parenteral support reduction and stool management for patients with MVID and SBS-IF.
📋 Key Facts
- Trial focused on a novel liquid formulation of crofelemer.
- In patients with MVID, crofelemer reduced required parenteral support (PS) by up to 27%.
- In patients with SBS-IF, crofelemer reduced required PS by up to 12.5%.
- Data showed reduction in stool volume/frequency and increased urine output.
- Trial was an investigator-initiated proof-of-concept trial.
Jaguar Health, Inc. announced an upcoming investor webcast scheduled for April 30, 2025, to review preliminary results from a proof-of-concept trial of its liquid crofelemer formulation.
📋 Key Facts
- Investor webcast scheduled for Wednesday, April 30, 2025, at 8:30 AM Eastern.
- Webcast will review preliminary results of an investigator-initiated trial (IIT) for a novel liquid formulation of crofelemer.
- The trial focuses on patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
- Data was previously presented by Dr. Mohamad Miqdady on April 26, 2025, at the 11th Annual ELITE PED-GI Congress.
Jaguar Health, Inc. filed an 8-K/A to amend a previous filing and disclose two significant financial events: an extension of a secured promissory note maturity date and a private equity exchange to reduce royalty obligations.
🚩 Red Flags
- Short-term liquidity pressure: The secured promissory note matures in July 2025 (less than 3 months from filing date).
- Equity dilution: Issuance of 1.29 million shares to settle a royalty obligation.
📋 Key Facts
- Maturity date for the $6,220,812.50 secured promissory note (held by Streeterville Capital, LLC) extended to July 20, 2025.
- Issued 1,290,000 shares of common stock in a privately negotiated exchange agreement.
- The equity issuance was used to reduce an outstanding royalty interest balance by $1,094,952.
- The note is held by the company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. announced its participation in the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi. The company's CEO will present an updated investor presentation during the conference.
📋 Key Facts
- The company is presenting at the 11th Annual Elite Ped-GI Congress 2025 from April 24 to April 26, 2025.
- Location of event: Abu Dhabi, UAR.
- CEO will present an updated investor presentation during the conference and in separate investor sessions.
- The filing includes Exhibit 99.1 (Investor Presentation dated April 2025).
Jaguar Health, Inc. announced its participation in the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi from April 24 to April 26, 2025. The company's CEO will present an updated investor presentation during the event.
📋 Key Facts
- Company scheduled to present at the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi, UAR.
- Event dates: April 24 to April 26, 2025.
- CEO will deliver an updated investor presentation during the conference and in separate investor sessions.
- The filing includes Exhibit 99.1 (Investor Presentation dated April 2025) under Item 7.01.
Jaguar Health, Inc. closed a private placement on March 31, 2025, involving the issuance of $3.4 million in convertible promissory notes and warrants to purchase up to 622,584 shares of common stock.
🚩 Red Flags
- Issuance of convertible debt can lead to significant future dilution for existing shareholders upon conversion.
📋 Key Facts
- Closing date of Private Placement: March 31, 2025
- Aggregate principal amount of Notes issued: approximately $3.4 million
- Instrument type: Convertible promissory notes and warrants
- Warrant coverage: Up to 622,584 shares of common stock
- Investors: Selected institutional and accredited investors
Jaguar Health, Inc. filed an 8-K to furnish its 2024 annual results via a press release. The filing is a routine disclosure of financial performance and does not contain specific material changes or adverse events.
📋 Key Facts
- The company issued a press release on March 31, 2025, announcing its full-year 2024 results.
- The report was signed by Lisa A. Conte, CEO & President.
- The filing includes Exhibit 99.1 containing the press release.
Jaguar Health, Inc. entered into a $3.4 million private placement of convertible promissory notes with selected accredited investors to fund working capital. The deal includes warrants and significant restrictive covenants, including a requirement that 100% of non-revenue outside investments be used for debt repayment.
🚩 Red Flags
- Extremely short maturity date (3 months), indicating urgent liquidity needs or a bridge financing structure.
- Restrictive covenant requiring 100% of non-revenue outside investments to be used for debt repayment, which may severely limit future operational flexibility.
- Debt covenants include restrictions on incurring any new indebtedness without 50.1% holder consent.
- Potential dilution from the immediate conversion rights and warrants (totaling over 1.2 million potential shares).
- High cost of capital including placement agent fees and warrant compensation.
📋 Key Facts
- Total aggregate principal amount of Notes: $3.4 million.
- Notes bear interest at 6% per annum and mature in three months (approx. June 2025).
- Conversion price: $5.535 for non-insiders; $5.555 for insiders.
- Warrants issued to investors: up to 622,598 shares at an exercise price of $5.41 (non-insiders) or $5.43 (insiders).
- Placement Agent (H.C. Wainwright & Co., LLC) receiving a 7% cash fee and 1% management fee.
- Insiders (CEO, CFO, and certain directors) are participating with $535,000 in the placement.
- Restrictive covenant: 100% of net proceeds from outside investments (excluding product sales revenue) must be used to repay the Notes.
Jaguar Health, Inc. has announced a 1-for-25 reverse stock split of its common stock, effective March 24, 2025. This action follows stockholder approval at a special meeting held on March 13, 2025.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing)
- Significant dilution of share count per unit, though total market cap remains unchanged
📋 Key Facts
- Reverse stock split ratio: 1-for-25
- Effective Date: March 24, 2025, at 12:01 am ET
- New CUSIP number: 47010C888
- No fractional shares will be issued; cash in lieu of fractions provided
- The split reduces the number of shares issuable upon exercise/vesting of options and warrants proportionally
- Trading continues on Nasdaq Capital Market on a reverse split-adjusted basis
Jaguar Health, Inc. held a special meeting of stockholders on March 13, 2025, where shareholders approved an amendment to the Certificate of Incorporation to authorize a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to boost share price to meet minimum exchange listing requirements (Nasdaq).
- High number of 'Against' votes relative to total shares represented (~20% opposition on the primary proposal).
📋 Key Facts
- Stockholders approved a reverse stock split ratio between 1-for-15 and 1-for-40.
- The Board of Directors has discretion to set the exact ratio within that range.
- Proposal 1 received 5,281,329 votes 'For' and 1,377,494 votes 'Against'.
- Total shares represented at meeting: 6,678,281 Common Stock and 99 Series J Preferred Stock.
- The company also approved the adjournment of the Special Meeting to solicit additional proxies if necessary.
Jaguar Health, Inc. has declared a dividend of shareholder rights (Class A and Class B Rights) that function as a 'poison pill' or shareholder rights plan. This is typically implemented to prevent hostile takeovers by making an acquisition prohibitively expensive for any entity acquiring more than 20% of the company.
🚩 Red Flags
- Implementation of a 'Poison Pill' often indicates the company is facing an imminent hostile takeover attempt or perceived threat from an activist investor.
- The extreme dilution and preferential terms of the Series K Preferred Stock (1,000x dividend multiplier) are highly non-standard and designed to make any acquisition extremely costly for a potential acquirer.
📋 Key Facts
- Board declared dividend of one Class A Right per share of Common Stock and one Class B Right per share of Non-Voting Common Stock on February 26, 2025.
- Rights are payable to stockholders of record as of March 10, 2025.
- Each Right allows the purchase of 0.001 shares of Series K Preferred Stock at $4.50 per 0.001 share ($4,500 per full share).
- The Rights include a 'Flip-In' provision triggered if an 'Acquiring Person' reaches 20% or more of the total voting power.
- Series K Preferred Stock carries significant preferential dividend rights (minimum $10.00/share or 1,000x cash dividends) and enhanced voting rights (electing two directors).
- Rights expire on February 26, 2026, unless redeemed or terminated earlier due to a merger or acquisition.
Jaguar Health, Inc. has amended an existing secured promissory note with Streeterville Capital, LLC to extend the maturity date of a $6.22 million debt obligation.
🚩 Red Flags
- Debt extension indicates a need for more time to meet repayment obligations, which can be a symptom of liquidity constraints.
- The debt is 'secured,' meaning the lender has a claim on company assets in the event of default.
📋 Key Facts
- The amendment was entered into on February 13, 2025.
- Original principal amount of the Note is $6,220,812.50.
- The maturity date has been extended to January 20, 2026.
- The note was originally issued on January 19, 2021.
- The borrower in the agreement is Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of Jaguar Health, Inc.
Jaguar Health, Inc. has amended a secured promissory note to extend its maturity date and entered into an agreement to issue common stock to settle royalty interest obligations.
🚩 Red Flags
- Debt maturity extension: The company is extending the deadline for a $6.2M debt obligation to July 20, 2025, suggesting potential liquidity constraints.
- Equity for liability reduction: Issuing common stock to settle royalty interests results in immediate dilution of existing shareholders.
📋 Key Facts
- Maturity date of the $6,220,812.50 secured promissory note held by Streeterville Capital, LLC extended to July 20, 2025.
- The Note Amendment was entered into on January 29, 2025, between Jaguar Health, Napo Pharmaceuticals (subsidiary), and Streeterville Capital, LLC.
- Issued 1,290,000 shares of common stock to a holder of royalty interest in exchange for a $1,094,952 reduction in the outstanding royalty balance.
- The equity issuance was conducted via a privately negotiated exchange agreement under Section 3(a)(9) of the Securities Act.